Success of the second edition of RESI Europe in Barcelona
The international meeting specializing in early stage investment achieves a good participation of startups and American investment companies
For the second consecutive year, Barcelona has been the host city of Redefining Every Stage Investments (RESI) Europe Barcelona 2025, one of the most important international conferences on partnering in life sciences, of North American origin.
The event, held from 1 to 3 April 2025, during one in-person day at the Hotel InterContinental Barcelona and two subsequent virtual days, is organized by Life Sciences Nation (LSN) and has been possible thanks to the support of Biocat, the Barcelona City Council and the Generalitat de Catalunya.
This year, RESI Europe Barcelona has brought together more than 450 attendees from nearly 350 companies from around the world, and has had more than 125 investment firms from international companies, especially from Europe and the United States.
A strategic meeting point for startups and international investors
The aim of the congress is to offer an exceptional opportunity for startups and scaleups in the healthcare sector, facilitating their connection with international investors actively seeking strategic alliances and investable projects.
Highlights of the 2025 edition include:
- The presence of more than 450 attendees, a slightly higher figure than last year.
- International participation: the meeting brought together 125 investment firms and nearly 350 companies from around the world.
- Global visibility for Catalan startups: the 44 emerging companies from the BioRegion of Catalonia had a platform to publicize their innovation internationally.
BioRegion startup Mowoot, winner of the Innovator's Pitch Challenge (IPC)
RESI Europe Barcelona included the Innovator’s Pitch Challenge (IPC), a competition where 14 startups from the BioRegion presented their technology to international investors.
Tecmed Mowoot was declared the winner of the competition, followed by Darwin Biomed in second place and Opportunity Health in third place, both based in Navarra. The prizes include attendance at other annual editions of the conference around the world, thus maximizing the contacts and investment opportunities offered by the LSN network. The prizes were awarded by Dennis Ford, President of Life Science Nation (LSN), Xavier Mayo, Head of the Barcelona Investment Office of the Barcelona City Council, and Robert Fabregat, CEO of Biocat.
Workshops, investor panels and networking spaces
The event also featured thirteen content sessions to explore the latest market trends, investment strategies and business best practices, with a panel on market access in healthtech, hosted by Biocat and moderated by Carmen Rios, CEO of Doctomatic, featuring a strong audience participation.
The discussion addressed the main challenges in bringing health technology innovations to market, including regulatory hurdles, coverage, coding, reimbursement and adoption pathways, as well as the role of data and digital tools in healthcare. According to Ana Maiques, CEO of Neuroelectrics, EU clinical assessments represent significant obstacles in bringing products to market, and the AI Act introduces additional requirements. In contrast, the FDA takes a more harmonized and consultative approach. Meike Bomhof, VP Market Access at Avania, highlighted that companies need to define regulatory and market access criteria from the early stages of defining the product's business model. Francisco Rodríguez, Medical Device Manager and Principal Auditor at Asphalion, stated that medical devices typically take 18 months to obtain approval, while in vitro diagnostics (IVDs) take 16 months.
A key event for innovation and investment in health
RESI Europe Barcelona was not only a platform for investment, but also a space for collaboration and innovation that reinforced Barcelona's role as a global hub in life sciences.